Loading...
XNYSRFL
Market cap47mUSD
Jan 08, Last price  
1.94USD
1D
-1.52%
1Q
-14.54%
IPO
-58.28%
Name

Rafael Holdings Inc

Chart & Performance

D1W1MN
XNYS:RFL chart
P/E
—
P/S
75.15
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.33%
Rev. gr., 5y
-33.59%
Revenues
637k
+128.32%
3,987,0005,589,0005,618,0004,371,0004,931,0004,910,0003,971,000410,000279,000637,000
Net income
-70m
L+3,628.20%
-467,000710,000138,000-11,649,000-4,924,000-6,945,000-25,149,000-124,658,000-1,876,000-69,941,000
CFO
-8m
L-28.33%
-571,00072,000-1,623,000-1,815,000-3,132,000-4,666,000-15,601,000-26,079,000-10,886,000-7,802,000
Dividend
Dec 18, 20090.02 USD/sh
Earnings
Mar 11, 2025

Profile

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
URL
https://rafaelholdings.com
IPO date
Mar 12, 2018
Employees
22
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑072015‑07
Income
Revenues
637
128.32%
279
-31.95%
410
-89.68%
Cost of revenue
13,178
15,322
25,792
Unusual Expense (Income)
NOPBT
(12,541)
(15,043)
(25,382)
NOPBT Margin
Operating Taxes
2,680
(255)
(15,314)
Tax Rate
NOPAT
(15,221)
(14,788)
(10,068)
Net income
(69,941)
3,628.20%
(1,876)
-98.50%
(124,658)
395.68%
Dividends
Dividend yield
Proceeds from repurchase of equity
(168)
(218)
110,092
BB yield
0.47%
0.47%
-275.71%
Debt
Debt current
2,314
15,000
Long-term debt
73
Deferred revenue
Other long-term liabilities
2,987
55
88
Net debt
(75,563)
(87,131)
(48,712)
Cash flow
Cash from operating activities
(7,802)
(10,886)
(26,079)
CAPEX
(143)
51,679
(2)
Cash from investing activities
(10,820)
21,211
(63,796)
Cash from financing activities
(179)
(15,218)
103,864
FCF
(15,718)
23,083
(3,551)
Balance
Cash
65,940
79,506
63,235
Long term investments
12,010
7,625
477
Excess cash
77,918
87,117
63,692
Stockholders' equity
(197,313)
(167,381)
(164,817)
Invested Capital
288,945
264,065
277,111
ROIC
ROCE
EV
Common stock shares outstanding
23,746
23,263
19,767
Price
1.49
-25.50%
2.00
-0.99%
2.02
-96.01%
Market cap
35,381
-23.96%
46,526
16.52%
39,930
-95.22%
EV
(36,109)
(44,269)
(12,091)
EBITDA
(12,316)
(14,965)
(25,310)
EV/EBITDA
2.93
2.96
0.48
Interest
248
6
Interest/NOPBT